Why Nomura Microscience (TSE: 6254) is worth paying attention to

For some speculators, the excitement of investing in a company that has the potential to reverse its fortunes is a big draw, so even a company with no revenue or profits and an underperforming track record can still manage to find investors. I can. In some cases, these stories can cloud investors’ minds and lead them to invest based on their emotions rather than the merits of a good company’s fundamentals. Although cash-rich companies may suffer losses for years, they must eventually generate profits. Otherwise, investors will move on and the company will decline.

Despite the era of blue-sky investing in tech stocks, many investors still employ traditional strategies.Buy shares in profitable companies such as nomura microscience (TSE: 6254). Profit is not the only metric to consider when investing, but it is worth evaluating companies that can consistently generate profits.

Check out our latest analysis for Nomura Microscience.

How fast is Nomura Microscience increasing its earnings per share?

If a company can continue to grow its earnings per share (EPS) over a long enough period of time, the stock price should eventually follow suit. This means that most successful long-term investors consider his EPS growth to be substantially positive. It must be acknowledged that Nomura Microscience has grown his EPS by 60% per year over the past three years. Although this kind of growth rate is not sustainable for long, it certainly attracts the attention of prospective investors.

Revenue growth is a good indicator that growth is sustainable and, when combined with high earnings before interest and tax (EBIT) margins, can help a company maintain a competitive advantage in the market. This is an excellent method. Nomura Micro Science shareholders can take confidence in the fact that EBIT margins have risen from his 11% to 15% and earnings are increasing. In our book, it’s a good sign of growth for him to check these two boxes.

You can see the company’s revenue and profit growth trends in the graph below. Click on the image for more details.

I don’t drive while looking in my rearview mirror, so this may be of interest to me. free Report showing Nomura Microscience analyst forecasts future profit.

Are Nomura Microscience insiders in line with all shareholders?

Insider investing always provides reassurance to the market, as it is imperative that company leaders act in the best interests of shareholders. So it’s good to see that Nomura Microscience insiders have significant capital invested in the stock. Specifically, it owns shares worth 6.9 billion yen. This significant investment should help increase the long-term value of the business. Although he owns only 3.5% of the company, this is still a significant amount at stake for the company to maintain its strategy of delivering value to shareholders.

Is Nomura Microscience worth putting on your watchlist?

Nomura Microscience’s achievements have been quite remarkable. This level of his EPS growth has done wonders for attracting investment, and the large insider investment in the company is just the icing on the cake. Rapid EPS growth can indicate that a business is reaching an inflection point, so there is potential opportunity here. So, based on this simple analysis, we think it’s worth considering putting Nomura Microscience on your Watchlist. Remember, there may still be risks. For example, we identified 1 warning sign for Nomura Microscience What you need to know.

Nomura Microscience certainly looks good, but if insiders have been buying up shares, it could become more attractive to more investors. If you want to know which companies have insider buying, then check out this selected selection of Japanese companies that not only boast strong growth, but also have recent insider buying.

Please note that the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.

Have feedback on this article? Curious about its content? contact Please contact us directly. Alternatively, email our editorial team at Simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts using only unbiased methodologies, and articles are not intended to be financial advice. This is not a recommendation to buy or sell any stock, and does not take into account your objectives or financial situation. We aim to provide long-term, focused analysis based on fundamental data. Note that our analysis may not factor in the latest announcements or qualitative material from price-sensitive companies. Simply Wall St has no position in any stocks mentioned.